|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis:A global survey of physicians'practice显示文摘AIM To examine treatment decisions of gastroenterologists regarding the choice of prescribing 5-aminosalycilates(5ASA) with corticosteroids(CS) versus corticosteroids alone for patients with active ulcerative colitis(UC). METHODS A cross-sectional questionnaire exploring physicians' attitude toward 5ASA + CS combination therapy vs CS alone was developed and validated. The questionnaire was distributed to gastroenterology experts in twelve countries in five continents. Respondents' agreement with stated treatment choices were assessed by standardized Likert scale. Background professional characteristics of respondents were analyzed for correlation with responses. RESULTS Six hundred and sixty-four questionnaires were distributed and 349 received(52.6% response rate). Of 340 eligible respondents, 221(65%) would continue 5ASA in a patient hospitalized for intravenous CS treatment due to a moderate-severe UC flare, while 108(32%) would stop the 5ASA(P < 0.001), and 11(3%) are undecided. Similarly, 62% would continue 5ASA in an out-patient starting oral CS. However, only 140/340(41%) would proactively start 5ASA in a hospitalized patient not receiving 5ASA before admission. Most(94%) physicians consider the safety profile of 5ASA as very good. Only 52% consider them inexpensive, 35% perceive them to be expensive and 12% are undecided. On multi-variable analysis, less years of practice and perception of a plausible additive mechanistic effect of 5ASA + CS were positively associated with the decision to continue 5ASA with CS. CONCLUSION Despite the absence of data supporting its benefit, most gastroenterologists endorse combination of 5ASA + CS for patients with active moderate-to-severe UC. Randomized controlled trials are needed to assess if 5ASA confer any benefit for these patients. | Shomron Ben-Horin Jane M Andrews Konstantinos H Katsanos Florian Rieder Flavio Steinwurz Konstantinos Karmiris Jae Hee Cheon Gordon William Moran Monica Cesarini Christian D Stone Doron Schwartz Marijana Protic Xavier Roblin Giulia Roda Min-Hu Chen Ofir Har-Noy Charles N Bernstein | 2017 | World Journal of Gastroenterology2017，23，16： | 3 |
| 2 | Yellow Pr-zircon Pigments:The Role of Praseodymium and of the Mineralizer显示文摘 | Giulia D N Giuseppe C Silvia A | 2004 | Journal of European Ceramic Society2004，24，14： | 1 |
| 3 | Self- assembling and antioxidant activity of some vitamin C derivatives 显示文摘 | PIERANDREA L N GIULIA C PATRIZIA P | 2000 | Colloids and Surfaces A: Physicochemical and Engineering Aspects2000，，167： | 1 |
| 4 | -Glucan of Can- dida albicans cell wall causes the subversion of human monocyte differentiation into dendritic: cells显示文摘 | ROBERTO N ANTONELLA T GIULIA R | 2007 | J Leuko Bio2007，82，5： | 1 |
| 5 | Concentrations of imipenem induce biofilm formation in a multidrug-resistant clinical isolate of Acinetobacter baumannii显示文摘 | ELISABETTA N LAURA S GIULIA F | 2009 | BMC Microbiology2009，9，： | 1 |
| 6 | Synthesis of novel 3,5-disubstituted-2-oxindole derivatives as antitumor agents against human nonsmall cell lung cancer显示文摘 | Giulia N Simona S Valentina M | 2013 | ACS medicinal chemistry letters2013，4，： | 1 |
| 7 | Adjuvant chemotherapy in curatively resected rectal cancer: How valid are the data?显示文摘BACKGROUND According to the result of the Cochrane review published in 2012,postoperative adjuvant chemotherapy(CTx)is associated with a survival benefit for rectal cancer patients operated for cure in comparison to patients who underwent only the surgical resection.AIM To analyze the quality of the data supporting the advantage of adjuvant CTx after surgery for rectal cancer.In the times of increasing health care costs,it is imperative to offer the patient an evidence-based therapy that justifies potential side effects as well as costs.METHODS Overall survival was selected as endpoint of interest.Among the 21 included papers which analyzed this endpoint,we identified those three publications which have the highest weights to influence the final result.The validity of these papers was analyzed using the CONSORT checklist for randomized controlled trials.We performed a second meta-analysis excluding the three analyzed studies(n=18)in order to assess their impact on the overall result of the original metaanalysis.Finally,we performed a third meta-analysis excluding all studies(n=16)which showed a statistically improved overall survival.RESULTS The detailed analysis of the three most relevant RCTs according to the items of the CONSORT checklist showed several pitfalls.In up to 47%of the items,inappropriate answers were found.Generally,a lack of information regarding therandomization procedure as well as the absence of allocation concealment,blinded set-up,of intention-to-treat analysis and omission of sample size calculation were common problems of the analyzed studies.The exclusion of these three studies from the meta-analysis did not affect the general result of the meta-analysis,still confirming a survival advantage after adjuvant chemotherapy.After exclusion of single studies with a statistically significant outcome improvement,the meta-analysis of the remaining 16 studies again shows a statistically significant result due in part to a large remaining sample size.CONCLUSION The three most powerful publications show substantial deficits.We suggest a more critical appraisal regarding the validity of single studies because a metaanalysis cannot overcome the limitations of individual trials by pooling treatment effect estimates to generate a single best estimate. | Giulia Manzini Fabius Hapke Ian N Hines Doris Henne-Bruns Michael Kremer | 2020 | World Journal of Gastrointestinal Oncology2020，12，4： | 0 |
| 8 | Observatory science with eXTP显示文摘In this White Paper we present the potential of the enhanced X-ray Timing and Polarimetry(eXTP) mission for studies related to Observatory Science targets. These include flaring stars, supernova remnants, accreting white dwarfs, low and high mass X-ray binaries, radio quiet and radio loud active galactic nuclei, tidal disruption events, and gamma-ray bursts. eXTP will be excellently suited to study one common aspect of these objects: their often transient nature. Developed by an international Consortium led by the Institute of High Energy Physics of the Chinese Academy of Science, the eXTP mission is expected to be launched in the mid 2020s. | Jean J.M.in 't Zand Enrico Bozzo JinLu Qu Xiang-Dong Li Lorenzo Amati Yang Chen Immacolata Donnarumma Victor Doroshenko Stephen A.Drake Margarita Hernanz Peter A.Jenke Thomas J.Maccarone Simin Mahmoodifar Domitilla de Martino Alessandra De Rosa Elena M.Rossi Antonia Rowlinson Gloria Sala Giulia Stratta Thomas M.Tauris Joern Wilms XueFeng Wu Ping Zhou Iván Agudo Diego Altamirano Jean-Luc Atteia Nils A.andersson M.Cristina Baglio David R.Ballantyne Altan Baykal Ehud Behar Tomaso Belloni Sudip Bhattacharyya Stefano Bianchi Anna Bilous Pere Blay Joao Braga Sφren Brandt Edward F.Brown Niccolo Bucciantini Luciano Burderi Edward M.Cackett Riccardo Campana Sergio Campana Piergiorgio Casella Yuri Cavecchi Frank Chambers Liang Chen Yu-Peng Chen Jér?me Chenevez Maria Chernyakova ChiChuan Jin Riccardo Ciolfi Elisa Costantini Andrew Cumming Antonino D'Aì Zi-Gao Dai Filippo D'Ammando Massimiliano De Pasquale Nathalie Degenaar Melania Del Santo Valerio D'Elia Tiziana Di Salvo Gerry Doyle Maurizio Falanga XiLong Fan Robert D.Ferdman Marco Feroci Federico Fraschetti Duncan K.Galloway Angelo F.Gambino Poshak Gandhi MingYu Ge Bruce Gendre Ramandeep Gill Diego G?tz Christian Gouiffès Paola Grandi Jonathan Granot Manuel Güdel Alexander Heger Craig O.Heinke Jeroen Homan Rosario Iaria Kazushi Iwasawa Luca Izzo Long Ji Peter G.Jonker Jordi José Jelle S.Kaastra Emrah Kalemci Oleg Kargaltsev Nobuyuki Kawai Laurens Keek Stefanie Komossa Ingo Kreykenbohm Lucien Kuiper Devaky Kunneriath Gang Li En-Wei Liang Manuel Linares Francesco Longo FangJun Lu Alexander A.Lutovinov Denys Malyshev Julien Malzac Antonios Manousakis Ian McHardy Missagh Mehdipour YunPeng Men Mariano Méndez Roberto P.Mignani Romana Mikusincova M.Coleman Miller Giovanni Miniutti Christian Motch Joonas Nättilä Emanuele Nardini Torsten Neubert Paul T.O'Brien Mauro Orlandini Julian P.Osborne Luigi Pacciani Stéphane Paltani Maurizio Paolillo Iossif E.Papadakis Biswajit Paul Alberto Pellizzoni Uria Peretz Miguel A.Pérez Torres Emanuele Perinati Chanda Prescod-Weinstein Pablo Reig Alessandro Riggio Jerome Rodriguez Pablo Rodríguez-Gil Patrizia Romano Agata Rózańska Takanori Sakamoto Tuomo Salmi Ruben Salvaterra andrea Sanna andrea Santangelo Tuomas Savolainen Stéphane Schanne Hendrik Schatz LiJing Shao andy Shearer Steven N.Shore Ben W.Stappers Tod E.Strohmayer Valery F.Suleimanov Jirí Svoboda F.-K.Thielemann Francesco Tombesi Diego F.Torres Eleonora Torresi Sara Turriziani andrea Vacchi Stefano Vercellone Jacco Vink Jian-Min Wang JunFeng Wang Anna L.Watts ShanShan Weng Nevin N.Weinberg Peter J.Wheatley Rudy Wijnands Tyrone E.Woods Stan E.Woosley ShaoLin Xiong YuPeng Xu Zhen Yan George Younes WenFei Yu Feng Yuan Luca Zampieri Silvia Zane andrzej A.Zdziarski Shuang-Nan Zhang Shu Zhang Shuo Zhang Xiao Zhang Michael Zingale | 2019 | Science China(Physics,Mechanics & Astronomy)2019，62，2： | 0 |
| 9 | Edmonton Symptom Assessment Scale may reduce medical visits in patients undergoing chemotherapy for breast cancer显示文摘BACKGROUND Adjuvant chemotherapy is recommended in high-risk breast cancer. However, no universally accepted guidelines exist on pre-chemotherapy assessment. In particular, the number and frequency of medical visits vary according to each institution’s policy. We hypothesised that the Edmonton Symptom Assessment Scale(ESAS) may have a favourable impact on the pre-treatment assessment in candidates for adjuvant chemotherapy.AIM To investigate whether the ESAS can be used to safely reduce the number of medical visits in women with breast cancer undergoing adjuvant chemotherapy.METHODS In a retrospectively prospective matched-pair analysis, 100 patients who completed the ESAS questionnaire before administration of adjuvant chemotherapy(ESAS Group) were compared with 100 patients who underwent chemotherapy according to the traditional modality, without ESAS(no-ESAS Group). Patients of the ESAS Group received additional visits before treatment if their ESAS score was > 3. The primary endpoint was the total number of medical visits during the entire duration of the chemotherapy period. The secondary endpoints were the occurrence of severe complications(grade 3-4) and the number of unplanned visits during the chemotherapy period.RESULTS The study variables did not statistically differ between patients of the ESAS Group and no-ESAS Group(age P = 0.880;breast cancer stage P = 0.56;cancer histology P = 0.415;tumour size P = 0.258;lymph node status P = 0.883;immunohistochemical classification P = 0.754;type of surgery P = 0.157), except for premenopausal status(P = 0.015). The study variables did not statistically differ between patients of the ESAS Group and no-ESAS Group regarding age, cancer stage, histology, tumour size, lymph node status, immunohistochemical classification, and type of surgery. Unplanned visits during the entire duration of chemotherapy were 8 in the ESAS Group and 18 in the no-ESAS Group visits(P = 0.035). Grade 3-4 toxicity did not differ between the study groups(P = 0.652). Forty-eight patients of the ESAS Group received additional visits due to an ESAS score > 3. The mean number of medical visits was 4.38 ± 0.51 in the ESAS Group and 16.18 ± 1.82 in the no-ESAS group(P < 0.001). With multivariate analysis, women of the ESAS group were more likely to undergo additional visits for an ESAS score > 3 if they were aged 60 or older, received a mastectomy, or had tumour stage Ⅱ/Ⅲ.CONCLUSION The ESAS score may safely reduce the number of medical visits in candidates for adjuvant chemotherapy for early breast cancer. Our results suggest that the ESAS score may be used for selecting a group of breast cancer patients for whom it is safe to reduce the number of medical visits in the setting of adjuvant chemotherapy. This may translate into several advantages, such as a more rational utilization of human resources and a possible reduction of coronavirus pandemic infection risk in oncologic patients. | Valeria Sanna Palma Fedele Giulia Deiana Maria G Alicicco Chiara Ninniri Anna N Santoro Antonio Pazzola Alessandro Fancellu | 2022 | World Journal of Clinical Oncology2022，13，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员